Association of VTN Genotype with Plasminogen Activator Inhibitor-1 Activity in Late-Onset Alzheimer’s Disease
Genes · 27.04.2026 · 17 (5) · 516
DOI: 10.3390/genes17050516 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 27.04.2026. Verfasst von Deniz Agirbasli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, 34098 Istanbul, Turkey. Hauptthemen laut MEDLINE: Alzheimer Disease, Plasminogen Activator Inhibitor 1, Vitronectin. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background/Objectives: Late-onset Alzheimer’s disease (LOAD) is a multifactorial neurodegenerative disorder involving the interaction of genetic and environmental factors. Dysregulation of the fibrinolytic system, particularly an increase in plasminogen activator inhibitor-1 (PAI-1) levels, may contribute to Alzheimer’s pathology. Vitronectin (VTN) regulates fibrinolysis by stabilizing PAI-1. This study investigated the relationships between plasma PAI-1 activity and VTN, SERPINE1 (PAI-1), and APOE gene variants in nineteen LOAD patients (>65 years) and ten cognitively normal age-matched control groups.
Methods
Targeted next-generation sequencing was used to analyze the VTN, APOE, and SERPINE1 genes in 19 LOAD patients and ten controls. Additionally, plasma PAI-1 activity was measured in both groups.
Results
Plasma PAI-1 activity was statistically significantly higher in LOAD patients compared to controls (p = 0.04). Targeted next-generation sequencing results showed that VTN 5′-UTR variants (rs7212814, rs1555584131, rs71135830, and rs11437594) were found in all patients and observed in 20% of controls (p = 0.0001). The VTN rs704 variant was detected in 84% of patients and 29% of controls (p = 0.001). VTN 5′-UTR variants showed Spearman correlation with PAI-1 activity (r = 1.0; p < 0.0001). SERPINE1 3′-UTR variants (rs11178, rs41423845) were found to be associated with the disease (p = 0.027; p = 0.0001). The APOEε3/ε4 genotype was present in 52.6% of patients and was not associated with PAI-1 activity. VTN variants showed an association with LOAD.
Conclusions
These findings suggest that VTN variants may contribute to LOAD pathogenesis by affecting PAI-1 and leading to fibrinolytic system dysregulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Genetics, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, 34098 Istanbul, Turkey.
- Department of Cardiology, School of Medicine, Istanbul Medeniyet University, Uskudar, 34700 Istanbul, Turkey.
- Department of Neurology, Sancaktepe Şehit Prof. Dr. Ilhan Varank Training and Research Hospital, Sancaktepe, 34785 Istanbul, Turkey.
- Department of Neurology, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Kadikoy, 34722 Istanbul, Turkey.
- Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Graduate School of Natural and Applied Sciences, Acibadem Mehmet Ali Aydinlar University, Atasehir, 34752 Istanbul, Turkey.
ORCID-Profile: Meltem Muftuoglu
Zitieren
APA
Agirbasli, D., Agirbasli, M., Cakir, M. E., & Muftuoglu, M. (2026). Association of VTN Genotype with Plasminogen Activator Inhibitor-1 Activity in Late-Onset Alzheimer’s Disease. Genes, 17(5), 516. https://doi.org/10.3390/genes17050516
Vancouver
Agirbasli D, Agirbasli M, Cakir ME, Muftuoglu M. Association of VTN Genotype with Plasminogen Activator Inhibitor-1 Activity in Late-Onset Alzheimer’s Disease. Genes. 2026;17(5):516. doi:10.3390/genes17050516
BibTeX
@article{Agirbasli2026,
author = {Agirbasli, Deniz and Agirbasli, Mehmet and Cakir, Mehmet Emin and Muftuoglu, Meltem},
title = {Association of VTN Genotype with Plasminogen Activator Inhibitor-1 Activity in Late-Onset Alzheimer’s Disease},
journal = {Genes},
year = {2026},
volume = {17},
number = {5},
pages = {516},
doi = {10.3390/genes17050516}
}
EUVIMED